NCT06463691View on ClinicalTrials.gov

Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

July 31, 2029

Conditions
MCL
Interventions
DRUG

BGB-11417

Sonrotoclax, orally, 320 mg once daily following a weekly ramp-up schedule

DRUG

BGB-3111

Zanubrutinib, orally, 320 mg total daily dose

DRUG

CD20

CD20mab is recommened as Rituximab as per the protocol, other CD20mab is also allowed.

Trial Locations (1)

Unknown

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER